Forte Biosciences (NASDAQ: FBRX) director receives 18,353 RSU equity award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Doberstein Stephen K reported acquisition or exercise transactions in this Form 4 filing.

Forte Biosciences, Inc. director Stephen K. Doberstein received a grant of 18,353 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents the right to receive one share of Forte Biosciences common stock.

All 18,353 RSUs will vest in a single installment on the date of the first annual meeting of stockholders that occurs after May 29, 2026, as long as Doberstein continues to serve as a “Service Provider” under the company’s 2021 Equity Incentive Plan through that date. After this award, he is reported as directly holding 18,353 RSUs.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Doberstein Stephen K

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	18,353	$0.00	--

Holdings After Transaction: Restricted Stock Units — 18,353 shares (Direct, null)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

Key Figures

RSUs granted: 18,353 units RSU exercise price: $0.00 per unit RSUs outstanding after grant: 18,353 units

3 metrics

RSUs granted 18,353 units Restricted Stock Units awarded to director on May 29, 2026

RSU exercise price $0.00 per unit Grant/award acquisition with no purchase price

RSUs outstanding after grant 18,353 units Total RSUs held directly following the reported transaction

Key Terms

Restricted Stock Units, Service Provider, 2021 Equity Incentive Plan, vesting

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Service Provider financial

"Subject to the Reporting Person's continuing as a Service Provider"

2021 Equity Incentive Plan financial

"as defined in the 2021 Equity Incentive Plan"

vesting financial

"one hundred percent (100%) of the RSUs subject to the award will vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 04:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doberstein Stephen K

(Last)

(First)

(Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS

TEXAS

75247

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/29/2026		A		18,353		⁽²⁾	⁽²⁾	Common Stock	18,353	$0	18,353	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Forte Biosciences (FBRX) disclose about Stephen Doberstein in this Form 4?

Forte Biosciences reported that director Stephen K. Doberstein received 18,353 Restricted Stock Units. These RSUs are a stock-based compensation award that can convert into shares of common stock if specific vesting conditions are met under the 2021 Equity Incentive Plan.

How many Forte Biosciences RSUs did Stephen Doberstein receive?

Stephen K. Doberstein received 18,353 Restricted Stock Units from Forte Biosciences. Each RSU corresponds to one share of the company’s common stock, providing equity-based compensation that aligns his interests with stockholders as the award vests over time based on continued service.

When do Stephen Doberstein’s Forte Biosciences RSUs vest?

All 18,353 RSUs vest on the date of the first annual meeting of Forte Biosciences stockholders after May 29, 2026. Vesting occurs only if Doberstein continues as a “Service Provider” under the 2021 Equity Incentive Plan through that annual meeting date.

What does each Forte Biosciences RSU granted to Stephen Doberstein represent?

Each RSU granted to Stephen K. Doberstein represents a contingent right to receive one share of Forte Biosciences common stock. The shares are delivered only after the RSUs vest, subject to his continued service through the specified future stockholder meeting.

Is Stephen Doberstein’s RSU grant in Forte Biosciences an open-market purchase or sale?

The 18,353 RSUs reported for Stephen K. Doberstein are a grant or award, not an open-market purchase or sale. The transaction code is “A,” indicating compensation-related acquisition rather than a discretionary market trade in Forte Biosciences shares.